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Introduction 
 The goal of study was to explore the synthesis of 1-(5-methylhexyl)-
2,3,8,9-tetrahydro-1H-naphtho[2,1-e]indol-6(7H)-one. The structure and ring 
designation of this molecule is shown in Figure 1.  
N
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1-(5-methylhexyl)-2,3,8,9-tetrahydro-1H-naphtho[2,1-e]indol-6(7H)-one
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Figure 1 
This molecule is designed to act as a fluorescent model for cholesterol. It 
mimics cholesterol in terms of size, shape, and hydrophobic nature. This molecule 
gains its fluorescent character by having a fluorophore imbedded within its 
structure.  
 The fluorophore embedded within the model is essentially the fluorophore 
1-(6-(dimethylamino)naphthalen-2-yl)propan-1-one, also called PRODAN, shown 
in Figure 2. 
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N
O
PRODAN
 
Figure 2 
 The two six-membered rings of PRODAN make up the B-ring and C-ring 
of the model. The amine is built into the five-membered D-ring, and the carbonyl 
functional group is attached to the A-ring of the model. A nine-step synthesis was 
explored in order to develop this model.  
1-(5-methylhexyl)-2,3,8,9-tetrahydro-1H-naphtho[2,1-e]indol-6(7H)-one 
was designed to be used as a cholesterol model in order to explore the cholesterol 
binding sites of the protein human serum albumin (HSA). HSA  has been shown 
to be involved in cholesterol transport.i  
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Background 
 Steroid hormones are terpene derivatives that are essential for cell 
signaling and homeostasis. The basic structure for all steroids is a four-fused ring 
system: three six-membered rings and one five-membered ring. The molecular 
precursor to all steroid hormones is cholesterol. The cholesterol structure as well 
as ring designation is shown in Figure 3. 
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Figure 3 
 Cholesterol is located in all human cells tissue, but it is only slightly 
water-soluble. It must, therefore, be transported throughout the body by various 
lipoproteins. The two primary classes of lipoproteins that transport cholesterol are 
low-density lipoproteins (LDLs) and high-density lipoproteins (HDLs). LDLs are 
the primary  transporters to cell tissue. High concentrations of LDLs can result in 
plaques that form on artery walls. HDLs transports scavenged cholesterol to the 
liver, where excess cholesterol can be disposed of. ii LDLs, HDLs, and cholesterol 
all play significant roles in heart disease.iii 
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 HDLs and LDLs are not the only proteins that transport cholesterol. The 
protein Human Serum Albumin (HSA) has been shown to play a significant role 
in cholesterol trafficking.iv HSA is the most abundant protein in blood plasma 
with a concentration of around 5 g/100 mL.v It has been shown that HSA does not 
promote cholesterol efflux as well as other proteins but due to the fact that it is 
present in much higher concentration than other cholesterol transporters it plays a 
significant role in cholesterol transport.vi  
 HSA is a 66 kDa monomer of 585 amino acids. HSA contains a large 
amount of α-helical structures as well as 17 disulfide bonds and a single 
tryptophan residue. HSA is divided into three homologous helical domains named 
I, II, and III. Each of these domains is further subdivided into A and B 
subdomains.vii  
The primary function of HSA is disputed but HSA is important in 
obtaining proper osmotic pressure and important in transport and regulatory 
processes. The substrates that bind to HSA include metals, fatty acids, amino 
acids, hormones, cholesterol, and many therapeutic drugs. viii HSA has been 
shown to contain eleven total binding sites for fatty acids. Up to seven of those 
binding sites can contain a long chain fatty acids simultaneously.ix  
 Because it plays such a vital role in fatty acid and cholesterol transport, 
HSA has been investigated in its role in heart disease. In fact, there is an 
association between the mortality rate and levels of HSA in serum. Low levels of 
HSA have been to correlated to high rates of mortality in coronary heart disease.x, 
xi
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Despite the fact that HSA plays a major role in cholesterol efflux, there 
has been very little investigation into the relationship between HSA and 
cholesterol. Current research suggests that cholesterol binds to two separate sites. 
One site in subdomain IIA and the other site in subdomain IIIA.xii It has been 
shown that these two sites are the two primary binding sites for drugs.xiii,xiv  
The goal of this research is to synthesize the fluorescent cholesterol analog 
that can be used to examine HSA-cholesterol binding properties. Because 
cholesterol binds so nonspecifically to HSA, the analog need only mimic 
cholesterol in terms of size, shape, hydrophobicity, and arrangement of polar 
groups.  
It should be noted that, currently, there are fluorescent cholesterol models. 
There are two major problems with the current analogs. The first observed 
problem is that a large number of the current models have low quantum 
fluorescent yield. The other problem is that in order for the models to gain 
fluorescent character, they have significant structural differences from 
cholesterol.xv  
Fluorescent cholesterol analogs have been used in specific protein studies 
as well as lipid membrane binding studies. Problems with the current models have 
arisen with both types of studies. In lipid membranes it has been shown that some 
models insert into the membrane upside down, or that the models do not interact 
with lipid rafts. In the case of protein binding sites, it has been shown that slight 
variations to the original cholesterol structures greatly reduce the binding affinity 
of the models. xvi,xvii,xviii HSA, a carrier protein, falls in-between these two 
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categories. The HSA-cholesterol binding sites possess a higher selectivity than 
lipid membranes but not the selectivity of specific protein binding sites. This is 
the reason why the model created in this study needed to only mimic cholesterol 
in terms of size, shape, hydrophobicity, and arrangement of polar groups. It is also 
important to note that HSA contains UV-absorbing chromophores, especially its 
tryptophan residue. Therefore a cholesterol analog must emit and absorb outside 
the range of tryptophan.  
N
O
PRODAN
N
O
1-(5-methylhexyl)-2,3,8,9-tetrahydro-1H-naphtho[2,1-e]indol-6(7H)-one
 
Figure 4 
The model created in this study, 1-(5-methylhexyl)-2,3,8,9-tetrahydro-1H-
naphtho[2,1-e]indol-6(7H)-one (Figure 4), is based on the molecular fluorophore 
PRODAN(1-(6-(dimethylamino)naphthalen-2-yl)propan-1-one).   PRODAN has 
actually been used to examine the binding properties of HSA.  PRODAN has been 
shown to bind to the drug binding site in the IIA and IIIA subdomains, the same 
sites cholesterol has been shown to bind to. Research suggests that interactions 
between PRODAN and HSA is largely due to hydrophobic and electrostatic 
interactions. xix    
Fluorescence resonance energy transfer (FRET) studies have been 
conducted using PRODAN and HSA, specifically with Trp-214 and Cys-34. This 
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study showed that low concentrations of palmitic acid in the solution increased the 
fluorescence of PRODAN without effecting the tryptophan fluorescence but  higher 
concentrations of palmitic acid had the opposite effect.  This allowed for the  
mapping out of the binding locations of PRODAN and palmitic acid in relation to 
Trp-214 and Cys-34.xx 
 PRODAN was first prepared in 1979 by Weber and Ferris. It is a flurophore 
that is sensitive to the polarity of its environment. The fluorescent nature of 
PRODAN involves two groups, an electron donating alkylamino group and an 
electron accepting carbonyl. These two groups are attached to an aromatic 
naphthalene ring.xxi  
N
O
PRODAN
N
O
Planar Model
 
Figure 5 
Transfer of electron density from the electron donating group to accepting groups 
creates an excited state with significant  fluorescent character . The Abelt lab has 
shown that if the amino group of PRODAN is constrained into a planar conformation 
(Figure 5) it possess nearly identical fluorescent characteristics to PRODAN. The 
twisted state, where the amino group is out of plane with the ring, however  possesses 
nearly no fluorescent character.xxii,xxiii Within the model for this study the amino 
group is constrained in a five-membered ring in the planar conformation and will 
possess similar fluorescent characteristics to PRODAN. 
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Experimental 
5-Bromonaphthalen-2-amine. 5-Bromonaphthalen-2-ol (7.23 g, 0.032 mol), 
NaHSO3 (6.32 g, 0.061 mol), and NaOH (1.22 g, 0.031 mol) were placed in an 
autoclave followed by NH4OH (60 mL). The autoclave was sealed and heated to 
151 ̊C (~300 psi) overnight.  The autoclave was allowed to cool to 60 ̊C and 
depressurized. The contents were extracted by rinsing with water and acetone. 
This mixture was poured into water (200 mL), and the mixture was stirred 
overnight to allow acetone to evaporate. The next day NaCl (25 g) was added to 
the mixture. The resulting precipitate was collected by suction filtration and then 
dissolved in CH2Cl2 (100 mL). HCl (50 mL, 10%) was added to the solution. A 
brown precipitate salt immediately forms and is collected through suction 
filtration. The precipitate is placed in aq. NaHCO3 (300 mL, 2%) and stirred for 3 
hours. The layers of the filtrate were separated, and the organic layer was 
concentrated in vacuo to obtain starting 5-bromonaphthalen-2-ol (3.46 g, 0.016 
mol). The precipitate in the NaHCO3 mixture is collected through suction 
filtration giving 5-bromonaphthalen-2-amine (3.05 g, 0.0137 mol, 81%, based on 
recovered starting material). 1H NMR (CDCl3) δ 8.03 (d, J= 8.8 Hz, 1H), 7.52 (d, 
J=8.2 Hz, 1 H), 7.49 (d, J=7.2 Hz, 1 H), 7.17 (t, J=7.0 Hz, 1 H), 7.00 (d, J=8.43 
Hz, 1H), 6.93 (s, 1H); 13C NMR (CDCl3) δ 145.08, 136.43, 128.77, 126.93, 
126.61, 126.53, 126.03, 123.03, 119.60, 108.89. 
 
N-(5-Bromonaphthalen-2-yl)methanesulfonamide. Pyridine (4.7 mL) is added 
with stirring to a solution of 5-bromonapthalen-2-amine (4.21 g, 0.019 mol) in 
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CH2Cl2 (60 mL) cooled to 0 ̊C. Next, a solution of methanesulfonyl chloride (3.27 
g, 0.029 mol) in CH2Cl2 (10 mL) is added dropwise. The mixture is  stirred at 0 ̊C 
for 1 hour, then stirred at room temperature for 1 hour. The mixture is poured into 
saturated aq. NaHCO3, and the layers are stirred together rapidly for 15 minutes. 
The product is extracted with CH2Cl2 (3x 50 mL). The combined organic layers 
are washed with 10% HCL (4x 50 mL), dried over Na2SO4, and concentrated in 
vacuo. The resulting solid was recrystallized in MeOH/H2O. Finally,  N-(5-
bromonaphthalen-2-yl)methanesulfonamide was dried under high vacuum at 
100 ̊C before the next step. (4.52 g,  0.015 mol, 79%). 1H NMR (CDCl3) δ 8.16 
(d, J=9.1 Hz, 1H), 7.75 (d, J=7.75 Hz, 1H), 7.68 (d, J=7.3 Hz, 1H), 7.53 (d, J=8.7 
Hz, 1H), 7.38 (s, 1H), 7.30 (t, J=7.9 Hz, 1H), 3.01 (s, 3H);  13C NMR (CDCl3) δ 
136.83, 135.31, 129.14, 129.06, 128.79, 127.61, 127.18, 122.61, 121.69, 116.07, 
39.32. 
  
N-(5-Bromonaphthalen-2-yl)-N-(2,2-diethoxyethyl)methanesulfonamide. 
Potassium carbonate (2.35 g, 0.017 mol) is added to a solution of N-(6-
bromonaphthalen-2-yl)methanesulfonamide (2.50g,  0.00833 mol) is added to 
DMF (10 mL) under Ar followed by addition of K2CO3 (1 g,  0.00725 mol). 2-
bromo-1,1-diethoxyethane (3 mL, 0.0116 mol) is added. The reaction mixture is 
heated overnight at 110 ̊C with stirring. The reaction is monitored by TLC.  
Another portion of 2-bromo-1,1-diethoxyethane (1 mL, 0.00387 mol) is added, 
and heating and stirring is continued overnight. A further portion of 2-bromo-1,1-
diethoxyethane (1 mL, 0.00387 mol) is added, and heating and stirring is 
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continued overnight. Additional K2CO3 (0.42 g, 0.00305 mol) and 2-bromo-1,1-
diethoxyethane (1 mL, 0.00387 mol) are added. When TLC analysis shows that 
the reaction is complete, the reaction is allowed to cool. The inorganic solids are 
removed by suction filtration, and the solid is washed with a small amount of 
CH2Cl2. The volatile solvent is removed in vacuo, and the higher boiling materials 
are removed under high vacuum (0.1 Torr, up to 145°C) distillation.   N-(5-
Bromonaphthalen-2-yl)-N-(2,2-diethoxyethyl) methanesulfonamide is collected 
with some solvent still present on the solid (3.91 g, 0.0940, 112%). 1H NMR 
(CDCl3) δ 8.27 (d, J=9.0 Hz, 1H), 7.86 (s, 1H) 7.80 (d, J=6.9 Hz, 1H), 7.79(d, 
J=7.95 Hz, 1H), 7.57 (d J=8.39, Hz 1H), 7.36 (t, J=7.61 Hz, 1H), 4.63 (t, J=5.4 
Hz, 1H) 3.88 (d, J=5.26 Hz, 2H), 3.64(q, J=7.71 Hz, 2H), 3.49 (q, J=7.6 Hz, 2H), 
3.01(s, 3H), 1.13 (t, J=6.91 Hz, 6); 13C NMR (CDCl3) δ 138.73, 134.91, 131,31, 
130,89, 129,05, 128.20, 127.67, 127.64, 127.34, 122.83, 101.24, 62.86, 53.55, 
38.66, 15.45  
 
6-Bromo-3-(methylsulfonyl)-3H-benzo[e]indole. The N-(5-Bromonaphthalen-2-
yl)-N-(2,2-diethoxyethyl)methanesulfonamide residue (~3.91 g, ~0.0940 mol) is 
dissolved in CH2Cl2 (20 mL) and boron trifluoride etherate (1.5 mL, 0.0122 mol) 
is added. The reaction is stirred at room temperature overnight. The reaction is 
monitored by TLC. The following day two more portions of boron trifluoride 
etherate (0.5 mL, 0.00407 mol) is added, and the reaction is stirred at room 
temperature overnight. A final portion of boron trifluoride etherate (0.5 mL, 
0.00407 mol)  is added. The  reaction mixture is poured slowly into saturated aq. 
  
11
NaHCO3 (200 mL) with vigorous stirring. Once the bubbling has stopped, 
CH2Cl2 (100 mL) is added to the mixture, and the layers are separated. The 
aqueous layer is extracted with CH2Cl2 (2x 50 mL). The organic layers are 
washed with H2O (2x 50 mL), dried over CaCl2, and concentrated in vacuo. 6-
Bromo-3-(methylsulfonyl)-3H-benzo[e]indole was collected (2.66 g,  0.00821 
mol, 87%). 1H NMR (CDCl3) δ 8.18 (m, 3 H), 7.81 (d, J=7.1 Hz, 1 H), 7.60 (d, 
J=2.9 Hz, 1H), 7.43 (t, J=7.9 Hz, 1H), 7.22 (d, J=2.86 Hz, 1 H), 3.17 (s, 3H); 13C 
NMR (CDCl3) δ 129.55, 129.12, 128.99, 127.35, 127.29, 126.74, 125.75, 123,78, 
123.32, 114, 32, 107.38, 41.90 
 
6-Bromo-3H-benzo[e]indole. The 6-Bromo-3-(methylsulfonyl)-3H-
benzo[e]indole  (2.66 g,  0.00821 mol) residue is taken up in 5% methanolic KOH 
(150 mL), and the reaction is refluxed overnight. The reaction is allowed to cool, 
and the mixture is poured into H2O (300 mL). The methanol is allowed to 
evaporate overnight. The resulting solid is collected via suction filtration, washed 
with water and air-dried. The filtrate is acidified with acetic acid (50 mL), NaCl is 
added, and the resulting solid is collected through suction filtration, washed with 
water, and air-dried giving N-(5-bromonaphthalen-2-yl)methanesulfonamide (140 
mg,  0.466 mmol). The first solid is purified by high vacuum (0.1 Torr, T ~ 200 
°C) sublimation giving 6-bromo-3H-benzo[e]indole (0.78g,  0.00317 mol,  28 %) 
From N-(5-bromonaphthalen-2-yl)methanesulfonamide (40% over 3 steps). 1H 
NMR (CDCl3) δ 8.21 (d, J=7.9 Hz, 1H), 8.03 (d, J=9.14 Hz, 1H), 7.71 (d, J=7.66 
Hz, 1H), 7.61 (d, J=9.1 Hz, 1H), 7.37 (t, J=7.46 Hz,  1H), 7.31 (s, 1H), 7.08 (s, 
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1H); 13C NMR (CDCl3) δ 129.73, 127.86, 127.81, 126.35, 123.76, 123.26, 123.23, 
123.17, 123.10, 122.12, 114.26, 102.39. 
 
6-bromo-3-(5-methylhexyl)-3H-benzo[e]indole. Sodium hydride (150 mg,  
0.00625 mol, 60% in oil) is added in one portion to a solution of 6-bromo-3H-
benzo[e]indole (0.78 g, 0.00317 mol) in DMF (15 mL). After the reaction is 
complete, 5-methylhexyl methanesulfonate (1.00 g, 0.00309 mol) is added in one 
portion. The reaction is stirred under N2 for several hours. Additional sodium 
hydride (70 mg,  0.0030mol) is added and stirred for 15 minutes. Then additional 
5-methylhexyl methanesulfonate (240 mg, 1.24 mmol) is added and stirred under 
N2 overnight. The next day TLC analysis show that the reaction is complete.  The 
next day the reaction mixture is diluted with hexanes (45 mL) and CH2Cl2 (15 
mL). The aqueous layer is additionally extracted with hexanes (20 mL) and 
CH2Cl2 (10 mL). The combined organic layer is washed with water (3 x 60 mL), 
then dried over CaCl2, and conc. in vacuo. The excess 5-methylhexyl 
methanesulfonate is removed by vacuum distillation (0.1 Torr, up to 190°C) 
leaving 6-bromo-3-(5-methylhexyl)-3H-benzo[e]indole (~1.04 g, 0.00302 mol,  
95.3%) which is used without further purification. 1H NMR (CDCl3) δ 8.22 (d, 
J=7.99 Hz, 1 H), 8.04 (d, J= 9.15 Hz, 1H), 7.71 (d, J= 7.16 Hz, 1H), 7.60 (d, J= 
9.52 Hz, 1H), 7.37 (t, J=7.73 Hz, 1H), 7.21 (d, J=2.38 Hz, 1H), 7.03 (d, J=2.67 
Hz, 1H), 4.22 (t, J=7.0 Hz, 2H), 1.86 (q, J=7.05 Hz, 2H), 1.52(m, J=6.6 Hz, 1H), 
1.31(p, J=7.8 Hz, 2H), 1.22 (p, J=7.1 Hz, 2H), 0.87(d, J=6.3 Hz, 6H); (CDCl3) δ 
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132.92, 129.96, 127.56, 126.87, 126.22, 123.77, 123.73, 122.95, 121.38, 113.01, 
112.77, 100.67, 46.98, 38.70, 31.24, 28.11, 24.95, 22.81.  
 
6-Bromo-3-(5-methylhexyl)-2,3-dihydro-1H-benzo[e]indole. 6-bromo-3-(5-
methylhexyl)-3H-benzo[e]indole (1.04 g, 3.02 mmol) is combined with AcOH 
(25 mL). NaBH3CN (2.0 g, 0.0317 mol) is added slowly to mixture, and the 
reaction is left to stir overnight under N2. The next day additional NaBH3CN (1 g, 
0.0159 mol) is added, and the reaction is stirred for several hours.  The product 
mixture is added dropwise to aq. sodium bicarbonate (300 mL, 40 g), and the 
mixture is stirred for 1 hr. The product was extracted with CH2Cl2 (3x 100 mL), 
washed with H2O (2x 100 mL), concentrated in  vacuo, and purified by high 
vacuum (0.1 Torr, up to 145 °C) distillation to give 6-bromo-3-(5-methylhexyl)-
2,3-dihydro-1H-benzo[e]indole (900 mg, 2.60 mol, 86%). 1H NMR (CDCl3) δ 
8.04 (d, J=8.8 Hz, 1H), 7.46(m, J=9.0 Hz, 2H), 7.19(t, J=7.9 Hz, 1H), 6.98(d,  
J=9.1 Hz, 1H), 3.55(t, J=8.5 Hz, 2H), 3.24(t, J=8.7 Hz, 2H), 3.17(t, J=7.3 Hz, 
2H), 1.59(m,  3H), 1.42(p, J=7.7 Hz, 2H), 1.26(p, J=7.1 Hz, 2H), 0.92(d, J=6.8 
Hz, 6H); 13C NMR (CDCl3) δ 151.46, 132.32, 127.92, 126.74, 126.21, 125.46, 
123.93, 122.21, 121.38, 111.87, 53.72, 49.76, 39.09, 28.24, 27.93, 27.35, 25.27, 
22.91. 
 
Ethyl 4-(3-(5-methylhexyl)-2,3-dihydro-1H-benzo[e]indol-6-yl)butanoate. 
NiCl2(Pd3)2 (176 mg, 2.69) is added to  6-bromo-3-(5-methylhexyl)-2,3-dihydro-
1H-benzo[e]indole (900 mg, 2.62) in DMAC (7 mL) under N2. The reaction is 
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stirred for 15 minutes until all the NiCl2(Pd3)2 dissolves.  4-Ethoxy-4-
oxobutylzinc bromide (8.8 mL, 0.5 M solution in THF, 4.4 mmol) is added to the 
mixture. Stirring continued for several hours. Additional NiCl2(Pd3)2 (90 mg, 
0.138 mmol) is added. After 15 minutes additional 4-ethoxy-4-oxobutylzinc 
bromide (5 mL,  0.5 M solution in THF, 2.5 mol) is added to the mixture. The 
reaction is monitored by TLC. Stirring continues overnight. The following day 
additional NiCl2(Pd3)2 (90 mg, 0.138 mol) is added. After 15 minutes additional 
4-ethoxy-4-oxobutylzinc bromide (5 mL, , 0.5 M solution in THF, 2.5 mmol)  is 
added to the mixture. Stirring continues overnight. The following day the mixture 
is poured into water (300 mL) and stirred for 1 hour. Salt is added to the mixture 
and then the precipitated solid is collected with suction filtration. The solid is 
washed with water, air dried and ethyl 4-(3-(5-methylhexyl)-2,3-dihydro-1H-
benzo[e]indol-6-yl)butanoate (1.33 g, 3.49 mol, >100%) is collected. 1H NMR 
(CDCl3) δ 7.87 (d, J=8.7 Hz, 1H), 7.46 (m, 1H), 7.01 (d, J=6.3 Hz, 1H), 6.95 (d, 
J=6.3 Hz, 1H), 4.12 (q, J=6.9 Hz, 2H), 3.5 (t, J=8.3 Hz, 2H), 3.24 (t, J=8.4 Hz, 
2), 3.15(t, J=7.1 Hz, 2H), 3.04(t, J=7.6 Hz, 2H), 2.29 (t, J=7.3 Hz, 2H), 2.06 (p, 
J=7.3 Hz, 2H), 1.58(m, 2H), 1.40(m, 1H), 1.35(m, 2H), 1.25(t, J=6.4 Hz, 3H), 
0.89(d, J=6.4 Hz, 6H); 13C NMR (CDCl3) δ  
 
1-(5-methylhexyl)-2,3,8,9-tetrahydro-1H-naphtho[2,1-e]indol-6(7H)-one. 
Ethyl 4-(3-(5-methylhexyl)-2,3-dihydro-1H-benzo[e]indol-6-yl)butanoate(1.33 g, 
3.49 mmol) is covered in polyphosphoric acid, heated to 110 ̊C, and stirred 
overnight. The following day the mixture is poured into water (400 mL) and 
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stirred for several hours. The precipitated solid is collected with suction filtration 
and air dried. The solid was purified by vacuum (0.1 Torr, T ~ 200 °C) 
sublimation giving 1-(5-methylhexyl)-2,3,8,9-tetrahydro-1H-naphtho[2,1-e]indol-
6(7H)-one (420 mg,  1.26 mol, 36%) (48% over two steps). 1H NMR (CDCl3) δ 
8.01 (d, J=8.5 Hz, 1H), 7.93 (d, J=8.9 Hz, 1H), 7.40 (d, J=8.3 Hz, 1H), 6.93(d, 
J=8.9 Hz, 1H), 3.61(t, J=8.6 Hz, 2H), 3.27(m, 4), 3.21(t, J=7.0 Hz, 2H), 2.68(t, 
J=5.9 Hz, 2H), 2.24(t, J=5.6 Hz, 2H), 1.61(q, J=7.4 Hz, 2H), 1.54 (m, 1H), 1.39 
(p, J=5.9 Hz, 2H), 1.24 (p, J=8.0 Hz, 2H), 0.89 (d, J=6.1 Hz, 6H). 
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Results and Discussion 
The 1-(5-methylhexyl)-2,3,8,9-tetrahydro-1H-naphtho[2,1-e]indol-6(7H)-
one cholesterol model has five main molecular components: the A-ring, B-ring, 
C-ring, D-ring, and alkyl chain tail. The B- and C-rings are the two six membered 
rings in the naphthalene of the starting compound 5-bromonaphthalen-2-ol. 
Previous work had allowed for successful synthesis of the A-ring using a Negishi 
coupling and Lewis acid ring closure. The alkyl chain was provided by the 
commercially available alcohol.  Three separate pathways were explored for the 
synthesis of the D-ring. (Figure 6) 
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Figure 6 
  
17
Each of the pathways was tested on the model compound, naphthalen-2-
amine. The Gassman indole synthesis employed the use of a sulfoxide and a [2,3]-
sigmatropic rearrangment as a means of cyclization. The problem with this 
synthesis arose in the difficulty of the removal in the thiol.   With the 
intramolecular Friedel-Crafts synthesis, the multiple reduction steps lead to low 
yields. The Sundberg indole synthesis was selected for the D-ring synthesis due to 
the highest yields and ease of reactions.  
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Scheme 1 
 The final target, Compound 10, 1-(5-methylhexyl)-2,3,8,9-tetrahydro-1H-
naphtho[2,1-e]indol-6(7H)-one, was synthesized over a ten-step process starting 
from 1, 5-bromonaphthalen-2-ol  (Scheme 1).  As mentioned above the B- and C-
rings were imbedded in  the 5-bromonaphthalen-2-ol starting material and the  D-
ring was added to the naphthalene base using the Sundberg indole synthesis. The 
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alkyl chain was attached to the amine within the D-ring, and finally the A-ring 
was added using a Negishi Coupling reaction followed by Lewis acid cyclization.   
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5-bromonaphthalen-2-ol 5-bromonaphthalen-2-amine
1 2
 
Scheme 2 
Compound 2 was prepared in 81% yield (Scheme 2).  Reactant  1 was 
recovered, and the yield was based on this recovery. Reactant 1  was prepared by 
Abelt lab.  The Bucherer reaction was performed on 1 to give 2. This reaction was 
performed in autoclave at >150 °C and ~300 psi overnight. Initially, the autoclave 
would not hold pressure, and the reaction would proceed with very low yields. 
Cleaning the autoclave and double-wrapping the O-ring with Teflon tape solved 
this problem.  1H and 13C confirmed the transformation. The appropriate aromatic 
peaks appeared (7-8 pmm) as well as ten carbon peaks. The same number of 
peaks with the same patterns as 1 appeared.  However, there were chemical shift 
changes consistent with the substitution of a greater resonance-electron donating 
group. 
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Figure 7 
The mechanism for the Bucherer reaction is of interest and is illustrated in 
Figure 7. First the sulfite adds to the keto resonance form 1a at the beta position 
to the carbonyl. After protonation, the alcohol 1c is formed.  After 
tautomerization, the carbonyl on the resonance form 1d suffers  nucleophilic 
attack by ammonia. The alcohol in 1f takes up a second hydrogen becoming a 
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good leaving group.  The hydronium ion leaves from 1g and the alpha carbon is 
deprotonated in 1h reforming one of the pi bonds. It is also possible that at these 
temperatures for the hydroxide to leave without protonation. Finally, aromaticity 
is restored when the sulfite leaves 1i resulting in product 2.  
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2 3
 
Scheme 3 
 Compound 3 was synthesized with a 79% yield. (Scheme 3) This reaction 
was performed in CH2Cl2 under CaCl2.  The mesylate functional group was 
successfully added to the amine of compound 2 through an addition-elimination 
mechanism.  Compound 3 was purified by recrystalization.  
  The identity of Compound 3 was confirmed by 1H and 13C NMR. The 1H 
spectra had the appropriate 1H aromatic peaks (7-8 ppm) and the strong singlet 
around 3 ppm indicating the methyl on the mesylate. The 13C spectra had the 
expected 11 carbon peaks. The next several steps were performed without 
purification after each step.  Purification was accomplished with Compound 6.   
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Scheme 4 
Compound 4 was prepared in over 100% yield  (Scheme 4). This apparent 
yield is due to the fact that not all of the DMF solvent could be removed from the 
sample. Initially,  quantitative amounts of NaH were used instead of K2CO3, but 
K2CO3 proved to give higher yields and was easier to use as additional portions of 
NaH had to be added with each addition of acetal. It is also imperative that pure 
DMF is used.  
This reaction was monitored by TLC analysis using  75% hexanes/ 25% 
EtOAc. The slower eluting reactant,  would become less intense through out the 
reaction, and the faster eluting product, would become more intense. Usually two 
to four additional amounts of acetal were required for the reaction to go to 
completion. This reaction proceeds by an SN2 mechanism where, after it has been 
deprotonated, the nitrogen’s lone pair attacks the carbon bearing the bromine on 
the acetal.  
The identity of Compound 4 was confirmed by 1H and 13C NMR. The 
appropriate 1H aromatic peaks were observed (7-8 ppm) as well as the mesylate 
peak around 3 ppm. The appropriate ethyl peaks were observed downshifted due 
to the oxygen (3-4 ppm). A distinctive doublet-triplet pattern was observed for the 
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added two-carbon chain. The expected 15 carbon peaks were observed in the 13C 
NMR. 
 
Br
N BF3
Ms
OEt
EtO
Br
N
Ms
N-(5-bromonaphthalen-2-yl)-N-(2,2-diethoxyethyl)methanesulfonamide 6-bromo-3-(methylsulfonyl)-3H-benzo[e]indole
4 5
 
Scheme 5 
 Compound 5 was produced at 87% yield (Scheme 5).  The Lewis acid, 
boron trifluoride, was used for the ring closure. Initially, polyphosphoric acid 
(PPA) was used, but boron triflouride proved to be easier to use as PPA is highly 
viscous.  
This reaction was monitored by TLC analysis. A solution of 4% EtOAc/ 
96% hexanes was used as the mobile phase.  It would generally take 3 additional 
additions of BF3 for the reactant spot to fully disappear. 
 The identity of Compound 5 was confirmed by 1H and 13C NMR. The 
appropriate aromatic peaks appeared (7-8 ppm) as well as the mesylate peak 
around 3. The confirmation of ring closure is the indole peaks at 7.2 ppm (J=2.9 
Hz) and at 7.6 ppm (J=2.9 Hz). The small J values are due to the hydrogen being a 
member of a 5-membered ring as well as the hydrogen’s proximity to 
electronegative nitrogen. This small J value is a good indicator of the presence of 
the indole. The expected 13 carbon peaks were observed in the 13C NMR.  
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Figure 8 
The mechanism for D-ring closure is worth noting and is shown in Figure 
8. One of the oxygens on 4 acts as a nucleophile and bonds with BF3.  The formed 
ethoxytrifluoroborate leaves in 4a and the electrons on the other oxygen help 
stabilize the cation that is formed. Then the pi electrons in the aromatic ring of 4b 
nucleophillically attack the cation forming the 5-membered ring. After 
aromaticity is restored in 4d, the remaining oxygen also bonds with BF3 and 
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leaves as ethoxytrifluoroborate in 4e. After further deprotationation, the indole 
that forms, Compound 5, is a stabilized heteroaromatic system. 
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Figure 9 
 It is essential that the mesylate functional group is present, and Figure 9 
illustrates this fact. Without this mesylate group the cation in the intermediate 
could rearrange as the electrons on the nitrogen could help stabilize the positive 
charge. This does not occur in the presence of the mesylate because those 
electrons are delocalized to the mesylate and do not contribute to the cation 
stability. The likelihood of rearrangment is very small. This allows for the pi-
electrons of the naphthalene to form the 5-membered ring.  
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Scheme 6 
Compound 6 was produced with 28% yield using this saponification 
reaction (Scheme 6). This compound was the first purified product since 
Compound 3. This step has the lowest yield of any in the synthesis. It is unclear 
whether this loss of yield occurs during the reaction itself or during the 
purification process. The reaction occurs in methanol at reflux and was purified 
by high vacuum sublimation. It should be noted that different reflux durations 
have lead to vastly different yields with the most effective being between 12-24 
hours. 
The identity of Compound 6 was confirmed by 1H and 13C NMR. The 
primary indicator that compound 6 was successfully made is the removal of the 
mesylate peak around 3 ppm. The indole peaks were observed at 7.31 ppm and 
7.08 ppm are still present in compound  6 as well as the appropriate aromatic 
peaks (7-8 ppm). The indole peaks appeared as singlet peaks on the NMR of 
compound 6.  The expected 12 carbon peaks were observed in the 13C NMR .  
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Scheme 7 
 Compound 7 was produced with 95% yield (Scheme 7).  The attachment 
of the alkyl chain proceeds using an SN2 mechanism. The reaction was monitored 
by TLC using 4% EtOAC/ 96% hexanes. Additional additions of alkyl chain as 
well as additional NaH had to be added to drive the reaction to completion. 
Generally, two of three additions of NaH and alkyl chain were required. Initially, 
this reaction would not proceed due to excess mesthanesulfonyl choloride present 
in the alkyl chain. This was solved by purification by distillation of the alkyl 
chain. 
The identity of Compound 7 was confirmed by 1H and 13C NMR. The 
indole peak was observed at 7.21 ppm (J=2.38 Hz) and at 7.03 (J=2.67 Hz). The 
alkyl peaks appeared between 1-2 ppm with one appearing at 4.2 ppm, 
downshifted due to the neighboring nitrogen. The expected 18 carbon peaks were 
observed in the 13C NMR. 
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Figure 10 
 Initially, the alkyl chain was to have the S chiral center configuration as 
depicted in Figure 10. Unfortunately, this stereoisomer was unable to be isolated 
or synthesized. Instead of using the racemic mixture of both stereoisomers the 
chiral center was removed all together. In Compound 7 the alkyl chain has  no 
chiral center.  
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Scheme 8 
  Compound 8 was produced in 86% yield (Scheme 8). This reduction was 
performed over two days. Two additional portions of NaBH3CN were added to 
ensure completion of the reaction. Initially, attempts to purify compound 8 with 
high vacuum sublimation failed as the product began to distill off the sublimation 
tip. So a high vacuum distillation was preformed as a means of purification.  
The identity of Compound 8 was confirmed by 1H NMR and 13C NMR. 
The disappearance of the indole peaks, the appearance of alkane peaks between 3-
  
28
4 ppm confirmed the reaction in Scheme 8 was successful. The expected 18 
carbon peaks were observed.  
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Scheme 9 
Compound 9 was reported in over 100% yield (Scheme 9).  It was 
synthesized using a Negishi coupling mechanism with NiCl2(Pd2)3 as the catalyst. 
Initially, the reaction would not proceed on other model molecules, but this was 
solved once the DMAC was purified by distillation. This reaction was monitored 
by TLC using 4% EtOAc/ 96% hexanes as the mobile phase. Additional 
NiCl2(Pd2)3 and ethoxy-4-oxobutylzinc bromide was added until the reactant spot 
disappeared on the TLC. 
The identity of Compound 9 was confirmed by 1H NMR. The most 
telling sign is the presence of a quartet around 4 ppm which indicates the presence 
of the α-carbon to the ester.  Although the 1H NMR showed all the proper peaks it 
also showed low levels of impurities in the sample. The 13C NMR sample was too 
crude to provide evidence of 9. 
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Scheme 10 
Compound 10 was produced in 36% yield. PPA acts as a Lewis acid for 
this ring closure (Scheme 10).  These final two steps were only performed once 
and further trials, in order to learn reactant and catalyst amounts as well as 
reaction duration, are needed to maximize the yields of these reactions. 
Compound 10  was purified by high vacuum sublimation.  
The identity of Compound 10 was confirmed by 1H NMR. Another sign 
that product is obtained is that in solution under UV light, compound 10 
fluoresces a blue-green color as the PRODAN molecule is now successfully 
imbedded into the model.  In total, from reactant compound 1 to product 
compound 10 a total percent yield of 10.2% was obtained.   
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Figure 11 
 The mechanism for the A-ring closure is worth nothing (Figure 11). This 
mechanism functions in a similar manner to that of the ring closure on the D-ring. 
A hydrogen from the Lewis acid PPA is attacked nucleophillically by a lone pair 
on the ester carbonyl group in 9. The carbonyl carbon is then attacked by pi 
electrons in the aromatic ring, creating a carbon-carbon bond sealing the 6-
membered ring in 9a. Aromaticity is restored in 9b. In a manner similar to a 
reverse aldol reaction the lone pair on the alcohol reforms a carbonyl and the 
OCH3+ acts as a leaving group in 9c. Finally, the hydrogen is removed from the 
carbonyl in 9d and the final product Compound 10  is obtained.  
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Conclusion 
The starting compound 1-(5-methylhexyl)-2,3,8,9-tetrahydro-1H-
naphtho[2,1-e]indol-6(7H)-one was prepared with a 10.2% yield from starting 5-
Bromonaphthalen-2-ol. The final product needs to be analyzed and characterized 
by fluorescence spectroscopy. Also, Scheme 6, Scheme 9, and Scheme 10 all need 
further examination. These three steps all resulted in the lowest yields, and 
drastically reduce the yield of the synthesis. The reaction time in Scheme 6 needs 
further examination in order to determine the proper amount of reflux and 
appropriate temperature. Scheme 9 and Scheme 10 were only performed once and 
further exploration of these reactions is necessary to maximize the yield. The 
proper duration of the reactions, the amount of reactants used, and the best 
possible purification technique all need to be examined.  Once these issues have 
been addressed the model can be used to examine cholesterol binding in HSA.  
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Appendix A 
 
1H and 13C NMR Spectra 
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Figure A1. 5-Bromonaphthalen-2-amine 1H-NMR     4.13   6.83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2. 5-Bromonaphthalen-2-amine 13C-NMR 
10 8 6 4 2 0 ppm  
200 150 100 50 0 ppm  
Br
NH2
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Figure A3. N-(5-Bromonaphthalen-2-yl)methanesulfonamide 1H-NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A4. N-(5-Bromonaphthalen-2-yl)methanesulfonamide  13C-NMR 
10 8 6 4 2 0 ppm  
200 150 100 50 0 ppm  
Br
H
N
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Figure A5. N-(5-Bromonaphthalen-2-yl)-N-(2,2-
diethoxyethyl)methanesulfonamide 1H-NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A6. N-(5-Bromonaphthalen-2-yl)-N-(2,2-
diethoxyethyl)methanesulfonamide 13C-NMR 
12 10 8 6 4 2 0 ppm  
200 150 100 50 0 ppm  
Br
N
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OEt
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Figure A7. 6-Bromo-3-(methylsulfonyl)-3H-benzo[e]indole 1H-NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A8. 6-Bromo-3-(methylsulfonyl)-3H-benzo[e]indole 13C-NMR 
12 10 8 6 4 2 0 ppm  
480354304
200 150 100 50 0 ppm  
Br
N
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Figure A9. 6-Bromo-3H-benzo[e]indole 1H-NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A10. 6-Bromo-3H-benzo[e]indole 13C-NMR 
12 10 8 6 4 2 0 ppm  
200 150 100 50 0 ppm  
482856960
Br
NH
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Figure A11. 6-bromo-3-(5-methylhexyl)-3H-benzo[e]indole. 1H-NMR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A12. 6-bromo-3-(5-methylhexyl)-3H-benzo[e]indole. 13C-NMR. 
12 10 8 6 4 2 0 ppm  
483401728
200 150 100 50 0 ppm  
313192448
Br
N
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Figure A13. 6-Bromo-3-(5-methylhexyl)-2,3-dihydro-1H-benzo[e]indole 1H-
NMR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A14. 6-Bromo-3-(5-methylhexyl)-2,3-dihydro-1H-benzo[e]indole  13C-
NMR. 
12 10 8 6 4 2 0 ppm  
200 150 100 50 0 ppm  
550125568
Br
N
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Figure A15. Ethyl 4-(3-(5-methylhexyl)-2,3-dihydro-1H-benzo[e]indol-6-
yl)butanoate 1H-NMR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A16. Ethyl 4-(3-(5-methylhexyl)-2,3-dihydro-1H-benzo[e]indol-6-
yl)butanoate 13C-NMR. (Crude) 
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Figure A17. 1-(5-methylhexyl)-2,3,8,9-tetrahydro-1H-naphtho[2,1-e]indol-6(7H)-
one 1H-NMR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A18. 1-(5-methylhexyl)-2,3,8,9-tetrahydro-1H-naphtho[2,1-e]indol-6(7H)-
one 13C-NMR. (Crude) 
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